EX-10.6





 Exhibit 10.6 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT
AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED. 
 STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT 

This STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT, dated as of [•], 202[•] (this “Agreement”), is by and between
General Electric Company, a New York corporation (“GE”), and GE HealthCare Technologies, Inc., a Delaware corporation (“HealthCare”). 

WHEREAS, GE currently owns all of the issued and outstanding shares of common stock, par value $0.01 per share, of HealthCare
(“HealthCare Common Stock”); 
 WHEREAS, pursuant to the Separation and Distribution Agreement, dated as of [•], 2022,
by and between GE and HealthCare (the “Separation and Distribution Agreement”), GE will distribute 80.1% of the issued and outstanding shares of HealthCare Common Stock to holders of shares of GE common stock on the applicable
record date, on a pro rata basis (the “Distribution”); 
 WHEREAS, in connection with the Distribution, HealthCare will
register shares of HealthCare Common Stock under the Exchange Act (as defined below) on a registration statement on Form 10; 
 WHEREAS,
following the Distribution, GE may effect distributions of any shares of HealthCare Common Stock that are not distributed in the Distribution (such shares not distributed in the Distribution, the “Retained Shares”) to GE
stockholders as dividends or in exchange for outstanding shares of GE common stock or through one or more subsequent exchanges of HealthCare Common Stock for GE debt held by GE creditors, including pursuant to one or more transactions Registered
under the Securities Act (as such terms are defined below); 
 WHEREAS, following the Distribution, GE may from time to time Sell any
Retained Shares pursuant to one or more transactions, including transactions Registered under the Securities Act; 
 WHEREAS, HealthCare
desires to grant to GE the Registration Rights (as defined below) for the Registrable Securities (as defined below), on the terms and subject to the conditions set forth in this Agreement; and 

WHEREAS, GE desires to grant to HealthCare a proxy to vote the Retained Shares in proportion to the votes cast by HealthCare’s other
stockholders, on the terms and subject to the conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing
and the mutual promises, covenants and agreements of the parties hereto, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 












 ARTICLE I 

DEFINITIONS 
 1.1
Defined Terms. As used in this Agreement, the following terms shall have the following meanings: 
 “AAA” has the
meaning set forth in Section 4.4(c). 
 “Action” means any claim, complaint, petition, hearing,
charge, demand, action, suit, countersuit, arbitration, inquiry, audit, assessment, proceeding or investigation by or before any Governmental Authority, including any Government Investigation. 

“Affiliate” of any Person means a Person that controls, is controlled by or is under common control with such Person. As used
herein, “control” of any entity means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such entity, whether through ownership of voting securities or other
interests, by Contract or otherwise; provided, however, that (i) HealthCare and the other members of the HealthCare Group shall not be considered Affiliates of GE or any of the other members of the GE Group and (ii) GE and
the other members of the GE Group shall not be considered Affiliates of HealthCare or any of the other members of the HealthCare Group. 

“Agreement” has the meaning set forth in the preamble to this Agreement. 

“Ancillary Filings” has the meaning set forth in Section 2.4(a)(i). 

“Arbitral Tribunal” has the meaning set forth in Section 4.4(c)(ii). 

“Block Trade” means an Underwritten Offering not involving any “road show” which is commonly known as a “block
trade.” 
 “Contract” means any oral or written contract, agreement or other legally binding instrument, including any
note, bond, mortgage, deed, indenture, commitment, lease, sublease, license, sublicense or joint venture agreement. 
 “Chosen Court
Claim” has the meaning set forth in Section 4.6. 
 “Chosen Courts” has the meaning set
forth in Section 4.6. 
 “Convertible or Exchange Registration” has the meaning set forth in
Section 2.7. 
 “Debt” means any indebtedness of any member of the GE Group, including debt
securities, notes, credit facilities, credit agreements and other debt instruments, including, in each case, any amounts due thereunder. 

“Demand Registration” has the meaning set forth in Section 2.1(a). 

“Decision on Interim Relief” has the meaning set forth in Section 4.4(c)(v). 

  
 2 













 “Dispute” or “Disputes” has the meaning set forth in
Section 4.4(b). 
 “Dispute Notice” has the meaning set forth in
Section 4.4(b). 
 “Distribution” has the meaning set forth in the recitals to this Agreement.

 “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and any successor thereto, and any rules and
regulations promulgated thereunder, all as the same shall be in effect from time to time. 
 “Exchange Offer” means an
exchange offer of Registrable Securities for outstanding securities of a Holder. 
 “Exchanges” means one or more Public
Exchanges or Private Exchanges. 
 “GE” has the meaning set forth in the preamble to this Agreement and shall include its
successors, by merger, acquisition, reorganization or otherwise. 
 “GE Group” means GE and each Person that is a direct or
indirect Subsidiary of GE as of immediately following the Distribution, and each Person that becomes a Subsidiary of GE after the Distribution (in each case other than any member of the HealthCare Group); provided that any Person shall cease
to be a member of the GE Group upon ceasing to be a direct or indirect Subsidiary of GE. 
 “Governmental Approvals” means
any notices, reports or other filings given to or made with, or any Consents, registrations or permits obtained from, any Governmental Authority. 

“Governmental Authority” means any federal, state, local, foreign, international or multinational government, political
subdivision, governmental, quasi-governmental authority of any nature (including any department, commission, board, bureau, agency, court, tribunal) or other body exercising legislative, judicial, regulatory, administrative or taxing authority,
arbitral body or official of any of the foregoing. 
 “Government Investigation” means any inquiry, investigation, probe,
audit or inspection conducted by a Governmental Authority. 
 “Holder” means GE or any of its Subsidiaries, so long as such
Person holds any Registrable Securities, and any Person owning Registrable Securities who is a Permitted Transferee of rights under Section 4.3. 

“HealthCare” has the meaning set forth in the preamble to this Agreement and shall include its successors, by merger,
acquisition, reorganization or otherwise. 
 “HealthCare Common Stock” has the meaning set forth in the recitals to this
Agreement. 

  
 3 













 “HealthCare Group” means (i) HealthCare and (ii) each Person that
will be a direct or indirect Subsidiary of HealthCare immediately prior to the Distribution, and (iii) each Person that becomes a Subsidiary of HealthCare after the Distribution (in each case other than any member of the GE Group). 

“HealthCare Notice” has the meaning set forth in Section 2.1(a). 

“HealthCare Public Sale” has the meaning set forth in Section 2.2(a). 

“HealthCare Takedown Notice” has the meaning set forth in Section 2.1(f). 

“Initiating Holder” has the meaning set forth in Section 2.1(a). 

“Interim Relief” has the meaning set forth in Section 4.4(c)(v). 

“Law” means any statute, law, regulation, ordinance, rule, judgment, rule of common law, order, decree, Governmental
Approval, concession, grant, franchise, license, directive, guideline, policy, requirement or other governmental restriction or any similar form of decision of, or determination by, or any interpretation or administration of any of the foregoing by,
any Governmental Authority, whether now or hereinafter in effect and, in each case, as amended. 
 “Loss” or
“Losses” has the meaning set forth in Section 2.9(a). 
 “Negotiation Period”
has the meaning set forth in Section 4.4(b). 
 “Participating Banks” means such investment banks
or other Persons that are not part of the GE Group that engage, directly or indirectly, in any Exchange with one or more members of the GE Group. 

“Permitted Transferee” means any Transferee and any Subsequent Transferee. 

“Person” means an individual, a general or limited partnership, a corporation, an association, a trust, a joint venture, an
unincorporated organization, a limited liability company, any other entity or any Governmental Authority. 
 “Piggyback
Registration” has the meaning set forth in Section 2.2(a). 
 “Private Exchange” means a
private exchange pursuant to which one or more members of the GE Group shall Sell some or all of their Registrable Securities to one or more Participating Banks in exchange, directly or indirectly, for any equity interest of GE or the satisfaction
of Debt, in a transaction or series of transactions not required to be Registered under the Securities Act. 
 “Prospectus”
means the prospectus included in any Registration Statement, all amendments and supplements to such prospectus, including post-effective amendments, and all other material incorporated by reference in such prospectus. 

  
 4 













 “Public Exchange” means a public exchange pursuant to which one or more
members of the GE Group shall Sell some or all of their Registrable Securities to one or more Participating Banks in exchange, directly or indirectly, for any equity interest of GE or the satisfaction of Debt, in a transaction or series of
transactions Registered under the Securities Act. 
 “Registrable Securities” means any Retained Shares and any securities
issued or issuable directly or indirectly with respect to, in exchange for, upon the conversion of or in replacement of the Retained Shares, whether by way of a dividend or distribution or stock split or in connection with a combination of shares,
recapitalization, merger, consolidation, exchange or other reorganization. The term “Registrable Securities” excludes any security (i) the offering and Sale of which has been effectively Registered under the Securities Act and
which has been Sold in accordance with a Registration Statement, (ii) that has been Sold pursuant to Rule 144 under the Securities Act, (iii) that (A) may be Sold pursuant to Rule 144 under the Securities Act without being subject to the
volume limitations in subsection (e) of such rule and (B) is held by a Holder of less than 1% of the then-issued and outstanding shares of HealthCare Common Stock (determined, in the case of GE or any of its direct or indirect
Subsidiaries, as applicable, as the aggregate number of Registrable Securities held by all members of the GE Group) or (iv) that has been sold by a Holder in a transaction in which such Holder’s rights under this Agreement are not, or
cannot be, assigned. 
 “Registration” means a registration with the SEC of the offer and Sale to the public of any
HealthCare Common Stock under a Registration Statement. The terms “Register,” “Registered” and “Registering” shall have a correlative meaning. 

“Registration Expenses” means all expenses incident to HealthCare’s performance of or compliance with this Agreement,
including all (i) registration, qualification and filing fees, (ii) expenses incurred in connection with the preparation, printing and filing under the Securities Act of the Registration Statement, any Prospectus and any issuer free
writing prospectus and the distribution thereof, (iii) the fees and expenses of HealthCare’s counsel and independent accountants (including the expenses of any comfort letters or costs associated with the delivery by HealthCare Group
members’ independent certified public accountants of comfort letters customarily requested by underwriters), (iv) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for
investment of the Shares under the state or foreign securities or blue sky laws and the preparation, printing and distribution of a Blue Sky Memorandum (including the related reasonable fees and expenses of counsel), (v) the costs and charges of any
transfer agent and any registrar, (vi) all expenses and application fees incurred in connection with any filing with, and clearance of an offering by, Financial Industry Regulatory Authority, Inc., (vii) printing expenses, messenger, telephone
and delivery expenses, (viii) internal expenses of HealthCare (including all salaries and expenses of employees of HealthCare performing legal or accounting duties), (ix) fees and expenses of listing any Registrable Securities on any securities
exchange on which shares of HealthCare Common Stock are then listed, and (x) the reasonable fees and expenses of one legal counsel chosen by GE or the Holders of a majority of the Registrable Securities included in a Demand Registration,
Piggyback Registration or Shelf Registration (including Block Trades), as applicable; but excluding any underwriting discounts or commissions attributable to the Sale of any Registrable Securities, any fees and expenses of any other counsel,
accountants or other persons retained or employed by any Holder, any fees and expenses of any counsel to the underwriters or dealer managers and any stock transfer taxes. 

  
 5 













 “Registration Period” has the meaning set forth in
Section 2.1(c). 
 “Registration Rights” means the rights of the Holders to cause HealthCare to
Register Registrable Securities pursuant to this Agreement. 
 “Registration Statement” means any registration statement of
HealthCare filed with, or to be filed with, the SEC under the rules and regulations promulgated under the Securities Act, including the related Prospectus, amendments and supplements to such registration statement, including post-effective
amendments, and all exhibits and all material incorporated by reference in such registration statement. 
 “Retained
Shares” has the meaning set forth in the recitals to this Agreement. 
 “Rules” has the meaning set forth in
Section 4.4(c). 
 “Sale” means the direct or indirect transfer, sale, assignment or other
disposition of a security. The terms “Sell” and “Sold” have correlative meanings. 

“SEC” means the U.S. Securities and Exchange Commission. 

“Securities Act” means the U.S. Securities Act of 1933, as amended, and any successor thereto, and any rules and regulations
promulgated thereunder, all as the same shall be in effect from time to time. 
 “Shares” means all shares of HealthCare
Common Stock that are beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by GE or any Permitted Transferee from time to time, whether or not held immediately following
the Distribution. 
 “Shelf Registration” means a Registration Statement of HealthCare for an offering to be made on a
delayed or continuous basis of HealthCare Common Stock pursuant to Rule 415 under the Securities Act. 
 “Subsequent
Transferee” has the meaning set forth in Section 4.3(b). 
 “Subsidiary” means, with
respect to any Person, any corporation, limited liability company, joint venture or partnership of which such Person (i) beneficially owns (within the meaning of Rule 13d-3 under the Exchange
Act), either directly or indirectly, more than fifty percent (50%) of (A) the total combined voting power of all classes of voting securities of such Person, (B) the total combined equity interests or (C) the capital or profit
interests, in the case of a partnership, or (ii) otherwise has the power to vote, either directly or indirectly, sufficient securities to elect a majority of the board of directors or similar governing body. 

“Takedown Notice” has the meaning set forth in Section 2.1(f). 

“Transferee” has the meaning set forth in Section 4.3(b). 

“Underwritten Offering” means a Registration in which securities of HealthCare are Sold to an underwriter or underwriters on
a firm commitment basis for reoffering to the public. 

  
 6 













 1.2 General Interpretive Principles. Whenever used in this Agreement, except as
otherwise expressly provided or unless the context otherwise requires, any noun or pronoun shall be deemed to include the plural as well as the singular and to cover all genders. Whenever the words “include,” “includes” or
“including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” Unless otherwise specified, the terms “hereof,” “herein,” “hereunder” and similar terms
refer to this Agreement as a whole (including the exhibits hereto), and references herein to Articles, Sections and Exhibits refer to Articles, Sections and Exhibits of this Agreement. The word “or” shall have the inclusive meaning
represented by the phrase “and/or.” The word “receipt” shall mean actual receipt or deemed duly given pursuant to Section 4.2. The reference to any form under the Securities Act or the Exchange Act shall include a reference
to any successor to such form. The reference to any rule under the Securities Act or the Exchange Act shall include a reference to any successor provision to such rule. Except as otherwise indicated, all periods of time referred to herein shall
include all Saturdays, Sundays and holidays; provided, however, that if the date to perform the act or give any notice with respect to this Agreement shall fall on a day other than a business day, such act or notice may be performed or
given timely if performed or given on the next succeeding business day. References to a Person are also to its successors and permitted assigns. The titles to Articles and headings of Sections contained in this Agreement have been inserted for
convenience of reference only and shall not be deemed to be a part of or to affect the meaning or interpretation of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as
jointly drafted by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement. 

ARTICLE II 

REGISTRATION RIGHTS 
 2.1
Registration. 
 (a) Request. Any Holder(s) of Registrable Securities (collectively, the “Initiating Holder”)
shall have the right (including, for the avoidance of doubt, in connection with its rights pursuant to Section 2.7) to request that HealthCare file a Registration Statement with the SEC on the appropriate registration form
for all or part of the Registrable Securities held by such Initiating Holder by delivering a written request to HealthCare specifying the aggregate number of shares of Registrable Securities such Initiating Holder wishes to Register (a
“Demand Registration”). HealthCare shall (i) within five (5) days of the receipt of such request, give written notice of such Demand Registration to all Holders of Registrable Securities (the “HealthCare
Notice”), (ii) use its reasonable best efforts to prepare and file a Registration Statement as expeditiously as possible in respect of such Demand Registration and in any event within thirty (30) days of receipt of such request, and
(iii) use its reasonable best efforts to cause such Registration Statement to become effective as expeditiously as possible. HealthCare shall include in such Registration all Registrable Securities that the Holders request to be included within
the ten (10) days following their receipt of the HealthCare Notice. 

  
 7 













 (b) Limitations of Demand Registrations. There shall be no limitation on the number
of Demand Registrations pursuant to Section 2.1(a); provided, however, that the Holder(s) may not require HealthCare to effect a Demand Registration within sixty (60) days after the effective date of a
previous registration by HealthCare, other than a Shelf Registration, effected pursuant to this Section 2.1. In the event that any Person shall have received rights to Demand Registrations pursuant to
Section 2.7 or Section 4.3, and such Person shall have made a Demand Registration request, such request shall be treated as having been made by the Holder(s). The Registrable Securities requested
to be Registered pursuant to Section 2.1(a) must represent (i) an aggregate offering price of Registrable Securities that is reasonably expected to equal at least $100,000,000 (or its equivalent if the Registrable
Securities are to be offered in an Exchange Offer) or (ii) all of the remaining Registrable Securities owned by the requesting Holder and its Affiliates. 

(c) Effective Registration. HealthCare shall be deemed to have effected a Registration for purposes of
Section 2.1(a) if the Registration Statement is declared effective by the SEC or becomes effective upon filing with the SEC, and remains effective until the earlier of (i) the date when all Registrable Securities
thereunder have been Sold and (ii) (x) in case of a Registration Statement that is not a Shelf Registration Statement, 60 days from the effective date of the Registration Statement or (y) 12 months from the effective date of the Shelf
Registration Statement (such period, as applicable, the “Registration Period”). No Registration shall be deemed to have been effective if the conditions to closing specified in the underwriting agreement or dealer-manager agreement,
if any, entered into in connection with such Registration are not satisfied by reason of any member of the HealthCare Group. If, during the Registration Period, such Registration is interfered with by any stop order, injunction or other order or
requirement of the SEC or other Governmental Authority or the need to update or supplement the Registration Statement, the Registration Period shall be extended on a
day-for-day basis for any period the Holder is unable to complete an offering as a result of such stop order, injunction or other order or requirement of the SEC or
other Governmental Authority. 
 (d) Underwritten Offering; Exchange Offer. If the Initiating Holder so indicates at the time of its
request pursuant to Section 2.1(a), such offering of Registrable Securities shall be in the form of an Underwritten Offering or an Exchange Offer and HealthCare shall include such information in the HealthCare Notice. In
the event that the Initiating Holder intends to Sell the Registrable Securities by means of an Underwritten Offering or Exchange Offer, the right of any Holder to include Registrable Securities in such Registration shall be conditioned upon such
Holder’s participation in such Underwritten Offering or Exchange Offer and the inclusion of such Holder’s Registrable Securities in the Underwritten Offering or Exchange Offer (provided that such Holder’s Registrable Securities can
only be excluded from such Underwritten Offering or Exchange Offer pursuant to the provisions of Section 2.1(e)). 

(e) Priority of Securities in an Underwritten Offering. If the managing underwriter or underwriters of a proposed Underwritten Offering,
including an Underwritten Offering from a Shelf Registration, pursuant to this Section 2.1 informs the Holders with Registrable Securities in the proposed Underwritten Offering in writing that, in its or their opinion, the
number of Registrable Securities requested to be included in such Underwritten Offering exceeds the number that can be Sold in such Underwritten Offering without being likely to have an adverse effect on the price, timing or distribution of the
Registrable Securities offered or the market for the Registrable Securities offered, then the number of Registrable Securities to be included in such Underwritten Offering shall be reduced to such number that can be Sold without such adverse effect
based on the 

  
 8 













 
recommendation of the managing underwriter or underwriters and the Registrable Securities to be included in such Underwritten Offering shall be: (i) first, Registrable Securities requested
by all members of the GE Group to be included in such Underwritten Offering on a pro rata basis calculated based on the number of shares requested to be registered by all members of the GE Group; (ii) second, Registrable Securities requested by
all other Holders to be included in such Underwritten Offering on a pro rata basis calculated based on the aggregate number of shares requested to be registered; and (iii) third, all other Registrable Securities requested and otherwise eligible
to be included in such Underwritten Offering (including Registrable Securities to be Sold for the account of HealthCare) on a pro rata basis calculated based on the aggregate number of shares requested to be registered. In the event the Initiating
Holder notifies HealthCare that such Registration Statement shall be abandoned or withdrawn, such Holder shall not be deemed to have requested a Demand Registration pursuant to Section 2.1(a), and HealthCare shall not be
deemed to have made a Demand Registration request pursuant to Section 2.1(a) and Section 2.1(c). 

(f) Shelf Registration. At any time after the date hereof when HealthCare is eligible to Register the applicable Registrable Securities
on Form S-3 and Holders may request Demand Registrations, the requesting Holders may request HealthCare to effect a Demand Registration as a Shelf Registration. Any Holder of Registrable Securities included on
a Shelf Registration shall have the right to request that HealthCare cooperate in a shelf takedown at any time, including an Underwritten Offering, by delivering a written request thereof to HealthCare specifying the number of shares of Registrable
Securities such Holder wishes to include in the shelf takedown (each, a “Takedown Notice”). HealthCare shall (i) within five (5) days of the receipt of a Takedown Notice for an Underwritten Offering, give written notice of
such Takedown Notice to all Holders of Registrable Securities included on such Shelf Registration (“HealthCare Takedown Notice”), and (ii) take all actions reasonably requested by such Holder, including the filing of a
Prospectus supplement and the other actions described in Section 2.4, in accordance with the intended method of distribution set forth in the Takedown Notice, as soon as reasonably practicable. If the takedown is an
Underwritten Offering, HealthCare shall use its reasonable best efforts to include in such Underwritten Offering all Registrable Securities that that the Holders request to be included within the two (2) days following their receipt of the
HealthCare Takedown Notice. If the takedown is an Underwritten Offering, the Registrable Securities requested to be included in a shelf takedown must represent (i) an aggregate offering price of Registrable Securities that is reasonably
expected to equal at least $100,000,000 or (ii) all of the remaining Registrable Securities owned by the requesting Holder and its Affiliates. Notwithstanding anything else to the contrary in this Agreement, the requirement to deliver a
HealthCare Takedown Notice and the piggyback rights described in this Section 2.1(f) shall not apply to an Underwritten Offering that constitutes a Block Trade. There shall be no limitations on the number of Underwritten
Offerings pursuant to a Shelf Registration; provided, that in no event shall HealthCare be required to effect, pursuant to this Section 2.01(f), during any 90-day period, more
than (A) two Block Trades or (B) more than one Underwritten Offering that is not a Block Trade pursuant to a Takedown Notice (it being understood, for the avoidance of doubt, that a Takedown Notice shall not count as a Demand Registration
request for purposes of the limit set forth in Section 2.01(b)). 

  
 9 













 (g) SEC Form. Except as set forth in the next sentence, HealthCare shall use its
reasonable best efforts to cause Demand Registrations to be Registered on Form S-3, and if HealthCare is not then eligible under the Securities Act to use Form S-3,
Demand Registrations shall be Registered on Form S-1 or Form S-4 (in the case of an Exchange Offer). If a Demand Registration is a Convertible or Exchange Registration,
HealthCare shall effect such Registration on the appropriate Form under the Securities Act for such Registrations. HealthCare shall use its reasonable best efforts to become eligible to use Form S-3 and, after
becoming eligible to use Form S-3, shall use its reasonable best efforts to remain so eligible. All Demand Registrations shall comply with applicable requirements of the Securities Act and, together with each
Prospectus included, filed or otherwise furnished by HealthCare in connection therewith, shall not contain any untrue statement of material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. 
 (h) With respect to any Registration Statement, whether filed or to be filed pursuant to this Agreement, if the
HealthCare board of directors in good faith shall reasonably determine, upon the advice of legal counsel, that maintaining the effectiveness of such Registration Statement or filing an amendment or supplement thereto (or, if no Registration
Statement has yet been filed, filing such a Registration Statement) would cause HealthCare to disclose material non-public information, which disclosure (x) would be required to be made in any
Registration Statement so that such Registration Statement would not be materially misleading, (y) would not be required to be made at such time but for the filing or effectiveness of such Registration Statement and (z) would be materially
detrimental to HealthCare or would materially interfere with any material financing, acquisition, corporate reorganization or merger or other similar transaction involving HealthCare or any of its subsidiaries, and that, as a result of such
potential disclosure or interference, it is in the best interests of HealthCare to defer the filing or effectiveness of such Registration Statement at such time or suspend the Holders’ use of any prospectus which is a part of the Registration
Statement (such disclosure, the “Disadvantageous Disclosure”), and (ii) HealthCare furnishes to the Holders a certificate signed by the chief executive officer of HealthCare to that effect, HealthCare may, for the shortest
period reasonably practicable, and in any event for not more than 30 consecutive calendar days (a “Blackout Period”), notify the Holders whose offers and Sales of Registrable Securities are covered (or to be covered) by such
Registration Statement that such Registration Statement is unavailable for use (or will not be filed as requested) (a “Blackout Notice”). Upon the receipt of any such Blackout Notice, the Holders shall forthwith discontinue use of
the Prospectus contained in any effective Registration Statement; provided that, if at the time of receipt of such Blackout Notice any Holder shall have Sold its Registrable Securities (or have signed a firm commitment underwriting agreement with
respect to the purchase of such shares) and the Disadvantageous Disclosure is not of a nature that would require a post-effective amendment to the Registration Statement, then HealthCare shall use its commercially reasonable efforts to take such
action as to eliminate any restriction imposed by federal securities Laws on the timely delivery of such Registrable Securities; provided, further, that, if implementation of such Blackout Period would impair the ability of GE, any member of the GE
Group or any of their Transferees to Sell its Registrable Securities in accordance with its or their intended method of distribution, as determined by GE in its sole discretion, then HealthCare may not impose such Blackout Period (and any Blackout
Period then in effect shall automatically expire) and HealthCare shall as soon as reasonably possible revise, amend and/or supplement the Registration Statement, as applicable, so that it does not include any misstatement of a material fact or omit
to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. When any Disadvantageous Disclosure as to which a Blackout Notice has been previously delivered shall
cease to be 

  
 10 













 
required, HealthCare shall as promptly as reasonably practicable notify the Holders and take such actions in respect of such Registration Statement as are otherwise required by this Agreement.
The Registration Period for any Registration Statement for which HealthCare has given notice of a Blackout Period shall be increased by the length of time of such Blackout Period. HealthCare shall not impose, in any
365-day period, a Blackout Period (A) more than once and (B) lasting, in the aggregate, in excess of 60 calendar days. 

2.2 Piggyback Registrations. 

(a) Participation. If HealthCare proposes to file a Registration Statement under the Securities Act with respect to any offering of
HealthCare Common Stock for its own account or for the account of any other Persons (other than a Registration (i) under Section 2.1, (ii) pursuant to a Registration Statement on Form
S-8 or Form S-4 or similar form that relates to a transaction subject to Rule 145 under the Securities Act, (iii) pursuant to any form that does not include
substantially the same information as would be required to be included in a Registration Statement covering the Sale of Registrable Securities, (iv) in connection with any dividend reinvestment or similar plan, (v) for the sole purpose of
offering securities to another entity or its security holders in connection with the acquisition of assets or securities of such entity or any similar transaction or (vi) in which the only HealthCare Common Stock being Registered is HealthCare
Common Stock issuable upon conversion of debt securities that are also being Registered) (a “HealthCare Public Sale”), then, as soon as reasonably practicable (but in no event less than fifteen (15) days prior to the proposed
date of filing such Registration Statement), HealthCare shall give written notice of such proposed filing to each Holder, and such notice shall offer such Holders the opportunity to Register under such Registration Statement such number of
Registrable Securities as each such Holder may request in writing (a “Piggyback Registration”). Subject to Section 2.2(a) and Section 2.2(c), HealthCare shall include in such
Registration Statement all such Registrable Securities that are requested to be included therein within ten (10) days after the receipt of any such notice; provided, however, that if, at any time after giving written notice of its
intention to Register any securities and prior to the effective date of the Registration Statement filed in connection with such Registration, HealthCare shall determine for any reason not to Register or to delay Registration of such securities,
HealthCare may, at its election, give written notice of such determination to each such Holder and, thereupon, (i) in the case of a determination not to Register, shall be relieved of its obligation to Register any Registrable Securities in
connection with such Registration, without prejudice, however, to the rights of any Holder to request that such Registration be effected as a Demand Registration under Section 2.1, and (ii) in the case of a
determination to delay Registration, shall be permitted to delay Registering any Registrable Securities for the same period as the delay in Registering such other shares of HealthCare Common Stock. No Registration effected under this
Section 2.2 shall relieve HealthCare of its obligation to effect any Demand Registration under Section 2.1. If the offering pursuant to a Registration Statement pursuant to this
Section 2.2 is to be an Underwritten Offering, then each Holder making a request for a Piggyback Registration pursuant to this Section 2.2(a) shall, and HealthCare shall use reasonable best efforts
to coordinate arrangements with the underwriters so that each such Holder may, participate in such Underwritten Offering. If the offering pursuant to such Registration Statement is to be on any other basis, then each Holder making a request for a
Piggyback Registration pursuant to this Section 2.2(a) shall, and HealthCare shall use reasonable best efforts to coordinate arrangements so that each such Holder may, participate in such offering on such basis.
HealthCare’s filing of a 

  
 11 













 
Shelf Registration shall not be deemed to be a HealthCare Public Sale; provided, however, that the proposal to file any Prospectus supplement filed pursuant to a Shelf Registration
with respect to an offering of HealthCare Common Stock for its own account or for the account of any other Persons will be a HealthCare Public Sale unless such offering qualifies for an exemption from the HealthCare Public Sale definition in this
Section 2.2(a); provided, further that if HealthCare files a Shelf Registration for its own account or for the account of any other Persons, HealthCare agrees that it shall use its reasonable best efforts to
include in such Registration Statement such disclosures as may be required by Rule 430B under the Securities Act in order to ensure that the Holders may be added to such Shelf Registration at a later time through the filing of a Prospectus
supplement rather than a post-effective amendment. 
 (b) Right to Withdraw. Each Holder shall (1) have the right to withdraw
such Holder’s request for inclusion of its Registrable Securities in any Underwritten Offering pursuant to this Section 2.2 at any time prior to the execution of an underwriting agreement with respect thereto, and
(2) be permitted to withdraw all or part of such Holder’s Registrable Securities from a Piggyback Registration at any time prior to the effective date thereof, in each case by giving written notice to HealthCare of such Holder’s
request to withdraw. 
 (c) Priority of Piggyback Registration. If the managing underwriter or underwriters of any proposed
Underwritten Offering of a class of Registrable Securities included in a Piggyback Registration informs HealthCare and the Holders in writing that, in its or their opinion, the number of securities of such class which such Holder and any other
Persons intend to include in such Underwritten Offering exceeds the number which can be Sold in such Underwritten Offering without being likely to have an adverse effect on the price, timing or distribution of the securities offered or the market
for the securities offered, then the securities to be included in such Underwritten Offering shall be reduced to such number that can be Sold without such adverse effect based on the recommendation of the managing underwriter or underwriters and the
securities to be included in the Underwritten Offering shall be (i) first, all securities of HealthCare or any other Persons for whom HealthCare is effecting the Underwritten Offering, as the case may be, proposes to Sell, (ii) second,
Registrable Securities requested by any member of the GE Group to be included in such Underwritten Offering on a pro rata basis calculated based on the number of shares requested to be registered by all members of the GE Group, (iii) third,
Registrable Securities requested by all other Holders to be included in such Underwritten Offering on a pro rata basis calculated based on the aggregate number of shares requested to be registered, and (iv) fourth, all other securities
requested and otherwise eligible to be included in such Underwritten Offering (including securities to be Sold for the account of HealthCare) on a pro rata basis calculated based on the aggregate number of shares requested to be registered. 

2.3 Selection of Underwriter(s), Etc. In any Underwritten Offering or Exchange Offer pursuant to Section 2.1
or Section 2.2 that is not a HealthCare Public Sale, GE or, in the event no member of the GE Group is participating in such Underwritten Offering or Exchange Offer, the Holders of a majority of the outstanding Registrable
Securities being included in the Underwritten Offering or Exchange Offer, shall select the underwriter(s), dealer-manager(s), financial printer, solicitation or exchange agent (if any) and, in consultation with GE, counsel to the Holder(s) for such
Underwritten 

  
 12 













 
Offering or Exchange Offer; provided, that GE, or the Holders of a majority of the outstanding Registrable Securities, as applicable, shall consult with HealthCare and consider
HealthCare’s suggestions, if any, in good faith in connection with such selection. In any HealthCare Public Sale, HealthCare shall select the underwriter(s), dealer-manager(s), financial printer, solicitation or exchange agent (if any) and GE
or, in the event no member of the GE Group is participating in such Underwritten Offering or Exchange Offer, the Holders of a majority of the outstanding Registrable Securities being included in the HealthCare Public Sale, shall select counsel to
the Holder(s). 
 2.4 Registration Procedures. 

(a) In connection with the Registration or Sale of Registrable Securities pursuant to this Agreement, through an Underwritten Offering or
otherwise, HealthCare shall use reasonable best efforts to effect or cause the Registration and the Sale of such Registrable Securities in accordance with the intended methods of Sale thereof and: 

(i) prepare and file the required Registration Statement including all exhibits and financial statements and, in the case of an Exchange
Offer, any document required under Rule 425 or Rule 165 with respect to such Exchange Offer (collectively, the “Ancillary Filings”) required under the Securities Act to be filed therewith, and before filing with the SEC a
Registration Statement or Prospectus, or any amendments or supplements thereto, (A) furnish to the underwriters or dealer-managers, if any, and to the Holders, copies of all documents prepared to be filed, which documents shall be subject to
the review and comment of such underwriters or dealer-managers and such Holders and their respective counsel, and provide such underwriters or dealers managers, if any, and such Holders and their respective counsel reasonable time to review and
comment thereon and (B) not file with the SEC any Registration Statement or Prospectus or amendments or supplements thereto or any Ancillary Filing to which the Holders or the underwriters or dealer-managers, if any, shall reasonably object;

 (ii) except in the case of a Shelf Registration or Convertible or Exchange Registration, prepare and file with the SEC such amendments
and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the Sale of all
of the Shares Registered thereon until the earlier of (A) such time as all of such Shares have been Sold in accordance with the intended methods of Sale set forth in such Registration Statement or (B) the expiration of nine (9) months
after such Registration Statement becomes effective; 
 (iii) in the case of a Shelf Registration, prepare and file with the SEC such
amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the
Sale of all Shares subject thereto for a period ending thirty-six (36) months after the effective date of such Registration Statement; 

  
 13 













 (iv) in the case of a Convertible or Exchange Registration, prepare and file with the SEC
such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to
the Sale of all of the Shares subject thereto until such time as the rules, regulations and requirements of the Securities Act and the terms of any applicable convertible securities no longer require such Shares to be Registered under the Securities
Act; 
 (v) notify the participating Holders and the managing underwriter or underwriters or dealer-managers, if any, and (if requested)
confirm such advice in writing and provide copies of the relevant documents, as soon as reasonably practicable after notice thereof is received by HealthCare (A) when the applicable Registration Statement or any amendment thereto has been filed
or becomes effective, when the applicable Prospectus or any amendment or supplement to such Prospectus has been filed, or any Ancillary Filing has been filed, (B) of any written comments by the SEC or any request by the SEC or any other
Governmental Authority for amendments or supplements to such Registration Statement or such Prospectus or any Ancillary Filing or for additional information, (C) of the issuance by the SEC of any stop order suspending the effectiveness of such
Registration Statement or any order preventing or suspending the use of any preliminary or final Prospectus or any Ancillary Filing or the initiation or threatening of any proceedings for such purposes, (D) if, at any time, the representations
and warranties of HealthCare in any applicable underwriting agreement or dealer-manager agreements cease to be true and correct in all material respects, or (E) of the receipt by HealthCare of any notification with respect to the suspension of
the qualification of the Registrable Securities for offering or Sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; 

(vi) as soon as reasonably practicable notify each selling Holder and the managing underwriter or underwriters or dealer-managers, if any,
when HealthCare becomes aware of the occurrence of any event as a result of which the applicable Registration Statement or the Prospectus included in such Registration Statement (as then in effect) or any Ancillary Filing contains any untrue
statement of a material fact or omits to state a material fact necessary to make the statements therein (in the case of such Prospectus and any preliminary Prospectus, in light of the circumstances under which they were made) not misleading or, if
for any other reason it shall be necessary during such time period to amend or supplement such Registration Statement or Prospectus or any Ancillary Filing in order to comply with the Securities Act and, in either case as soon as reasonably
practicable thereafter, prepare and file with the SEC, and furnish without charge to the selling Holder and the managing underwriter or underwriters or dealer-managers, if any, an amendment or supplement to such Registration Statement or Prospectus
or any Ancillary Filing which will correct such statement or omission or effect such compliance; 
 (vii) use its reasonable best efforts to
prevent or obtain the withdrawal of any stop order or other order suspending the use of any preliminary or final Prospectus; 
 (viii) as
soon as reasonably practicable incorporate in a Prospectus supplement or post-effective amendment such information as the managing underwriters or dealer-managers, if any, and the Holders may reasonably request in order to permit the intended method
of distribution of the Registrable Securities; and make all required filings of such Prospectus supplement or post-effective amendment as soon as reasonably practicable after being notified of the matters to be incorporated in such Prospectus
supplement or post-effective amendment; 

  
 14 













 (ix) furnish to each selling Holder and each underwriter or dealer-manager, if any, without
charge, as many conformed copies as such Holder or underwriter or dealer-manager may reasonably request of the applicable Registration Statement and any amendment or post-effective amendment thereto, including financial statements and schedules, all
documents incorporated therein by reference and all exhibits (including those incorporated by reference); 
 (x) deliver to each selling
Holder and each underwriter or dealer-manager, if any, without charge, as many copies of the applicable Prospectus (including each preliminary Prospectus) and any amendment or supplement thereto as such Holder or underwriter or dealer-manager may
reasonably request (it being understood that HealthCare consents to the use of such Prospectus or any amendment or supplement thereto by each selling Holder and the underwriters or dealer-managers, if any, in connection with the offering and Sale of
the Registrable Securities covered by such Prospectus or any amendment or supplement thereto) and such other documents as such selling Holder or underwriter or dealer-manager may reasonably request in order to facilitate the Sale of the Registrable
Securities by such Holder or underwriter or dealer-manager; 
 (xi) on or prior to the date on which the applicable Registration Statement
is declared effective or becomes effective, use its reasonable best efforts to register or qualify, and cooperate with each selling Holder, the managing underwriter or underwriters or dealer-managers, if any, and their respective counsel, in
connection with the registration or qualification of such Registrable Securities for offer and Sale under the securities or “Blue Sky” laws of each state and other jurisdiction of the United States as any selling Holder or managing
underwriter or underwriters or dealer-managers, if any, or their respective counsel reasonably request, and in any foreign jurisdiction mutually agreeable to HealthCare and the participating Holders, in writing and do any and all other acts or
things reasonably necessary or advisable to keep such registration or qualification in effect for so long as such Registration Statement remains in effect and so as to permit the continuance of Sales and dealings in such jurisdictions of the United
States for so long as may be necessary to complete the distribution of the Registrable Securities covered by the Registration Statement; provided that HealthCare will not be required to qualify generally to do business in any jurisdiction
where it is not then so qualified or to take any action which would subject it to taxation or general service of process in any such jurisdiction where it is not then so subject; 

(xii) in connection with any Sale of Registrable Securities that will result in such securities no longer being Registrable Securities,
cooperate with each participating Holder and the managing underwriter or underwriters or dealer-managers, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be Sold and not bearing any
restrictive Securities Act legends; and to register such Registrable Securities in such denominations and such names as such selling Holder or the underwriters or dealer-managers, if any, may request at least two (2) business days prior to such
Sale of Registrable Securities; provided that HealthCare may satisfy its obligations hereunder without issuing physical stock certificates through the use of the Depository Trust Company’s Direct Registration System; 

  
 15 













 (xiii) cooperate and assist in any filings required to be made with the Financial Industry
Regulatory Authority, Inc. and each securities exchange, if any, on which any of HealthCare’s securities are then listed or quoted and on each inter-dealer quotation system on which any of HealthCare’s securities are then quoted, and in
the performance of any due diligence investigation by any managing underwriter or underwriter or dealer-manager (including any “qualified independent underwriter”) that is required to be retained in accordance with the rules and
regulations of each such exchange, and use its reasonable best efforts to cause the Registrable Securities covered by the applicable Registration Statement to be registered with or approved by such other governmental agencies or authorities as may
be necessary to enable the seller or sellers thereof or the managing underwriter or underwriters or dealer-managers, if any, to consummate the Sale of such Registrable Securities; 

(xiv) not later than the effective date of the applicable Registration Statement, provide a CUSIP number for all Registrable Securities and
provide the applicable transfer agent with printed certificates for the Registrable Securities which are in a form eligible for deposit with The Depository Trust Company; provided that HealthCare may satisfy its obligations hereunder without
issuing physical stock certificates through the use of the Depository Trust Company’s Direct Registration System; 
 (xv) obtain for
delivery to and addressed to each selling Holder and to the managing underwriter or underwriters or dealer-managers, if any, opinions from outside counsel or the general counsel for HealthCare, in each case dated the effective date of the
Registration Statement or, in the event of an Underwritten Offering, the date of the closing under the underwriting agreement or, in the event of an Exchange Offer, the date of the closing under the dealer-manager agreement or similar agreement or
otherwise, and in each such case in customary form and content for the type of Underwritten Offering or Exchange Offer, as applicable; 

(xvi) in the case of an Underwritten Offering or Exchange Offer, obtain for delivery to and addressed to HealthCare and the managing
underwriter or underwriters or dealer-managers and, to the extent requested, each participating Holder, a comfort letter from HealthCare’s or other applicable independent certified public accountants in customary form and content for the type
of Underwritten Offering or Exchange Offer, dated the date of execution of the underwriting agreement or dealer-manager agreement, or, if none, the date of commencement of the Exchange Offer, and brought down to the closing, whether under the
underwriting agreement or dealer-manager agreement, if applicable, or otherwise; 
 (xvii) in the case of an Exchange Offer that does not
involve a dealer-manager, provide to each participating Holder such customary written representations and warranties or other covenants or agreements as may be requested by any participating Holder comparable to those that would be included in an
underwriting agreement or dealer-manager agreement; 

  
 16 













 (xviii) use its reasonable best efforts to comply with all applicable rules and regulations
of the SEC and make generally available to its security holders, as soon as reasonably practicable, but no later than ninety (90) days after the end of the twelve (12)-month period beginning with the first day of HealthCare’s first quarter
commencing after the effective date of the applicable Registration Statement, an earnings statement satisfying the provisions of Section 11(a) of the Securities Act and the rules and regulations promulgated thereunder and covering the period of
at least twelve (12) months, but not more than eighteen (18) months, beginning with the first month after the effective date of the Registration Statement; 

(xix) provide and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by the applicable Registration
Statement from and after a date not later than the effective date of such Registration Statement; 
 (xx) cause all Registrable Securities
covered by the applicable Registration Statement to be listed on each securities exchange on which any of HealthCare’s securities are then listed or quoted and on each inter-dealer quotation system on which any of HealthCare’s securities
are then quoted; 
 (xxi) provide (A) each Holder participating in the Registration, (B) the underwriters (which term, for
purposes of this Agreement, shall include a Person deemed to be an underwriter within the meaning of Section 2(11) of the Securities Act), if any, of the Registrable Securities to be Registered, (C) the Sale or placement agent therefor, if
any, (D) the dealer-manager therefor, (E) counsel for such underwriters or agent or dealer-manager, and (F) any attorney, accountant or other agent or representative retained by such Holder or any such underwriter or dealer-manager,
as selected by such Holder, the opportunity to participate in the preparation of such Registration Statement, each Prospectus included therein or filed with the SEC, and each amendment or supplement thereto, and to require the insertion therein of
material, furnished to HealthCare in writing, which in the reasonable judgment of such Holder(s) and their counsel should be included; and for a reasonable period prior to the filing of such Registration Statement, upon receipt of such
confidentiality agreements as HealthCare may reasonably request, make available upon reasonable notice at reasonable times and for reasonable periods for inspection by the parties referred to in (A) through (F) above, all pertinent financial
and other records, pertinent corporate and other documents and properties of HealthCare that are available to HealthCare, and cause all of HealthCare’s officers, directors and employees and the independent public accountants who have certified
its financial statements to make themselves available at reasonable times and for reasonable periods to discuss the business of HealthCare and to supply all information available to HealthCare reasonably requested by any such Person in connection
with such Registration Statement as shall be necessary to enable them to exercise their due diligence responsibility, subject to the foregoing; 

(xxii) to cause the executive officers of HealthCare to participate in customary “road show” presentations that may be reasonably
requested by the managing underwriter or underwriters or dealer-managers in any Underwritten Offering or Exchange Offer and otherwise to facilitate, cooperate with, and participate in each proposed offering contemplated herein and customary selling
efforts related thereto; 

  
 17 













 (xxiii) comply with all requirements of the Securities Act, Exchange Act and other
applicable Laws, rules and regulations, as well as applicable stock exchange rules; and 
 (xxiv) take all other customary steps reasonably
necessary to effect the Registration, offering and Sale of the Registrable Securities. 
 (b) As a condition precedent to any Registration
hereunder, HealthCare may require each Holder as to which any Registration is being effected to furnish to HealthCare such information regarding the distribution of such securities and such other information relating to such Holder, its ownership of
Registrable Securities and other matters as HealthCare may from time to time reasonably request in writing. Each such Holder agrees to furnish such information to HealthCare and to cooperate with HealthCare as reasonably necessary to enable
HealthCare to comply with the provisions of this Agreement. 
 (c) GE agrees, and any other Holder agrees by acquisition of such Registrable
Securities, that, upon receipt of any written notice from HealthCare of the occurrence of any event of the kind described in Section 2.4(a)(vi), such Holder will forthwith discontinue the Sale of Registrable Securities
pursuant to such Registration Statement until such Holder’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 2.4(a)(vi), or until such Holder is advised in writing by HealthCare
that the use of the Prospectus may be resumed, and if so directed by HealthCare, such Holder will deliver to HealthCare (at HealthCare’s expense) all copies, other than permanent file copies then in such Holder’s possession, of the
Prospectus covering such Registrable Securities current at the time of receipt of such notice. In the event HealthCare shall give any such notice, the period during which the applicable Registration Statement is required to be maintained effective
shall be extended by the number of days during the period from and including the date of the giving of such notice to and including the date when each seller of Registrable Securities covered by such Registration Statement either receives the copies
of the supplemented or amended Prospectus contemplated by Section 2.4(a)(vi) or is advised in writing by HealthCare that the use of the Prospectus may be resumed. 

2.5 Holdback Agreements. To the extent requested in writing by the managing underwriter or underwriters of any Underwritten Offering and
to the extent the Initiating Holder signs a lock-up agreement, HealthCare agrees not to, and shall use reasonable best efforts to obtain agreements (in the underwriters’ customary form) from its
directors, executive officers and any beneficial owner or owners (within the meaning of Rule 13d-3 under the Exchange Act) of five percent (5%) or more of HealthCare Common Stock that has a
representative on the board of directors of HealthCare not to, directly or indirectly offer, Sell, pledge, contract to Sell (including any short Sale), grant any option to purchase or otherwise Sell any equity securities of HealthCare or enter into
any hedging transaction relating to any equity securities of HealthCare, during the ninety (90) days beginning on pricing date of such Underwritten Offering (except as part of such Underwritten Offering or any Distribution or pursuant to
registrations on Form S-8 or Form S-4) unless the managing underwriter or underwriters otherwise agree to a shorter period. Each person subject to the restrictions of
the preceding sentence shall receive the benefit of any shorter “lock-up” period or permitted exceptions agreed to by the managing underwriter or underwriters for any Underwritten Offering and the
terms of such lock-up agreements shall govern such person in lieu of the preceding sentence. 

  
 18 













 2.6 Underwritten Offerings; Exchange Offers. If requested by the managing underwriter
or underwriters of any Underwritten Offering or dealer-managers of any Exchange Offer, HealthCare shall enter into an underwriting agreement or dealer-manager agreement with such underwriters or dealer-managers for such offering; provided,
however, that no Holder shall be required to make any representations or warranties to HealthCare or the underwriters or dealer-managers (other than representations and warranties regarding such Holder and such Holder’s intended method
of distribution) or to undertake any indemnification obligations to HealthCare or the underwriters or dealer-managers with respect thereto, except as otherwise provided in Section 2.9. 

2.7 Convertible or Exchange Registration; Registration Rights with Participating Banks. 

(a) If any Holder of Registrable Securities offers any options, rights, warrants or other securities issued by it or any other Person that are
offered with, convertible into or exercisable or exchangeable for any Registrable Securities, the Registrable Securities underlying such options, rights, warrants or other securities shall be eligible for Registration pursuant to
Section 2.1 and Section 2.2 (a “Convertible or Exchange Registration”). 

(b) If one or more members of the GE Group decides to engage, directly or indirectly, in an Exchange with one or more Participating Banks,
HealthCare shall, upon GE’s request, enter into a registration rights agreement with the Participating Banks in connection with such Exchange, as applicable, on terms and subject to conditions consistent with this Agreement (other than the
voting provisions contained in Article III) and reasonably satisfactory to HealthCare and the GE Group. 
 2.8 Registration
Expenses Paid By HealthCare. In the case of any Registration of Registrable Securities required pursuant to this Agreement (including any Registration that is delayed or withdrawn) or proposed Underwritten Offering pursuant to this Agreement,
HealthCare shall pay all Registration Expenses regardless of whether the Registration Statement becomes effective or the Underwritten Offering is completed. 

2.9 Indemnification. 
 (a)
Indemnification by HealthCare. HealthCare agrees to indemnify and hold harmless, to the full extent permitted by law, each Holder, such Holder’s Affiliates and their respective officers, directors, employees, advisors, and agents and
each Person who controls (within the meaning of the Securities Act or the Exchange Act) such Persons from and against any and all losses, claims, damages, liabilities (or actions in respect thereof, whether or not such indemnified party is a party
thereto) and expenses, joint or several (including reasonable costs of investigation and legal expenses) (each, a “Loss” and collectively “Losses”) arising out of or based upon (i) any untrue or alleged untrue
statement of a material fact contained in any Registration Statement under which the Sale of such Registrable Securities was Registered under the Securities Act (including any final or preliminary Prospectus contained therein or any amendment
thereof or supplement thereto or any documents incorporated by reference therein), or any such statement made in any free writing prospectus (as defined in Rule 405 under the Securities Act) that HealthCare has filed or is required to file pursuant
to Rule 433(d) under the Securities Act, or (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary 

  
 19 













 
to make the statements therein (in the case of a Prospectus, preliminary Prospectus or free writing prospectus, in light of the circumstances under which they were made) not misleading;
provided, however, that HealthCare shall not be liable to any particular indemnified party in any such case to the extent that any such Loss arises out of or is based upon an untrue statement or alleged untrue statement or omission or
alleged omission made in any such Registration Statement in reliance upon and in conformity with written information furnished to HealthCare by such indemnified party expressly for use in the preparation thereof. This indemnity shall be in addition
to any liability HealthCare may otherwise have without duplication. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Holder or any indemnified party and shall survive the Sale of such
securities by such Holder. 
 (b) Indemnification by the Selling Holder. Each selling Holder agrees (severally and not jointly) to
indemnify and hold harmless, to the full extent permitted by law, HealthCare, its directors, officers, employees, advisors, and agents and each Person who controls HealthCare (within the meaning of the Securities Act and the Exchange Act) from and
against any Losses arising out of or based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration Statement under which the Sale of such Registrable Securities was Registered under the Securities Act
(including any final or preliminary Prospectus contained therein or any amendment thereof or supplement thereto or any documents incorporated by reference therein), or any such statement made in any free writing prospectus that HealthCare has filed
or is required to file pursuant to Rule 433(d) under the Securities Act, or (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a
Prospectus, preliminary Prospectus or free writing prospectus, in light of the circumstances under which they were made) not misleading to the extent, but, in each case (i) or (ii), only to the extent, that such untrue statement or omission is
made in reliance upon and conformity with any information furnished in writing by such selling Holder to HealthCare specifically for inclusion in such Registration Statement, Prospectus, preliminary Prospectus or free writing prospectus. In no event
shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder (or the fair value of the security received in an Exchange Offer) under the Sale of the Registrable
Securities giving rise to such indemnification obligation. This indemnity shall be in addition to any liability the selling Holder may otherwise have without duplication. Such indemnity shall remain in full force and effect regardless of any
investigation made by or on behalf of HealthCare or any indemnified party. 
 (c) Conduct of Indemnification Proceedings. Any Person
entitled to indemnification hereunder will (i) as soon as reasonably practicable give written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that any delay or failure to so notify
the indemnifying party shall relieve the indemnifying party of its obligations hereunder only to the extent that it is materially prejudiced by reason of such delay or failure) and (ii) permit such indemnifying party to assume the defense of
such claim with counsel reasonably satisfactory to the indemnified party; provided, however, that any Person entitled to indemnification hereunder shall have the right to select and employ separate counsel and to participate in the
defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless (i) the indemnifying party has agreed in writing to pay such fees or expenses, (ii) the indemnifying party shall have failed to
assume the defense of such claim 

  
 20 













 
within a reasonable time after receipt of notice of such claim from the Person entitled to indemnification hereunder and employ counsel reasonably satisfactory to such Person, (iii) the
indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, or
(iv) in the reasonable judgment of any such Person, based upon advice of its counsel, a conflict of interest may exist between such Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the
indemnifying party in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person). If such defense
is not assumed by the indemnifying party, the indemnifying party will not be subject to any liability for any settlement made without its consent, provided that such consent may not be unreasonably withheld, conditioned or delayed. If the
indemnifying party assumes the defense, the indemnifying party shall not have the right to settle such action without the consent of the indemnified party, which consent may not be unreasonably withheld, conditioned or delayed. No indemnifying party
shall consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of an unconditional release from all liability in respect to
such claim or litigation. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of
more than one separate firm at any one time (in addition to local counsel) from all such indemnified party or parties unless (x) the employment of more than one counsel has been authorized in writing by the indemnifying party or parties,
(y) an indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it that are different from or in addition to those available to the other indemnified parties or (z) in the
reasonable judgment of an indemnified party, based upon advice of its counsel, a conflict of interest may exist between such indemnified party and the other indemnified parties, in each of which cases the indemnifying party shall be obligated to pay
the reasonable fees and expenses of such additional counsel or counsels. 
 (d) Contribution. If for any reason the indemnification
provided for in Section 2.9(a) or Section 2.9(b) is unavailable to an indemnified party or insufficient to hold it harmless as contemplated by Section 2.9(a) or
Section 2.9(b), then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Loss in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and the indemnified party on the other hand. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the indemnifying party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement
or omission. Notwithstanding anything in this Section 2.9(d) to the contrary, no indemnifying party (other than HealthCare) shall be required pursuant to this Section 2.9(d) to contribute any
amount in excess of the amount by which the net proceeds received by such indemnifying party from the Sale of Registrable Securities in the offering to which the Losses of the indemnified parties relate (before deducting expenses, if any) exceeds
the amount of any damages which such indemnifying party has otherwise been required to pay by reason of such untrue statement or 

  
 21 













 
omission. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 2.9(d) were determined by pro rata allocation or by
any other method of allocation that does not take account of the equitable considerations referred to in this Section 2.9(d). Notwithstanding the provisions of this Section 2.9(d), no selling
Holder hereunder shall be required to contribute any amount in excess of the dollar amount of the net proceeds received by such Holder (or the fair value of the security received in an Exchange Offer) under the Sale of the Registrable Securities
giving rise to such indemnification obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation. The amount paid or payable by an indemnified party hereunder shall be deemed to include, for purposes of this Section 2.9(d), any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or
proceeding. If indemnification is available under this Section 2.9, the indemnifying parties shall indemnify each indemnified party to the full extent provided in Section 2.9(a) and
Section 2.9(b) without regard to the relative fault of said indemnifying parties or indemnified party. 
 2.10
Reporting Requirements; Rule 144. Until the expiration or termination of this Agreement in accordance with its terms, HealthCare shall be and remain in compliance with the periodic filing requirements imposed under the SEC’s rules and
regulations, including the Exchange Act, and any other applicable Laws or rules, and shall timely file such information, documents and reports as the SEC may require or prescribe under Section 13 or 15(d) (whichever is applicable) of the
Exchange Act. If HealthCare is not required to file such reports, it will, upon the request of any Holder, make publicly available such necessary information for so long as necessary to permit Sales pursuant to Rule 144 or Regulation S under the
Securities Act, and it will take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to Sell Registrable Securities without Registration under the Securities Act within the
limitation of the exemptions provided by (a) Rule 144 or Regulation S under the Securities Act, or (b) any rule or regulation hereafter adopted by the SEC. From and after the date hereof through the first anniversary of the date upon which
no Holder owns any Registrable Securities, HealthCare shall forthwith upon request furnish any Holder (i) a written statement by HealthCare as to whether it has complied with such requirements and, if not, the specifics thereof, (ii) a
copy of the most recent annual or quarterly report of HealthCare, and (iii) such other reports and documents filed by HealthCare with the SEC as such Holder may reasonably request in availing itself of an exemption for the Sale of Registrable
Securities without registration under the Securities Act. 
 2.11 Other Registration Rights. HealthCare shall not grant to any Persons
the right to request HealthCare to Register any equity securities of HealthCare, or any securities convertible into or exercisable or exchangeable for such securities, whether pursuant to “demand,” “piggyback,” or other rights,
unless such rights are subject and subordinate to the rights of the Holders under this Agreement. 

  
 22 













 ARTICLE III 

VOTING RESTRICTIONS 

3.1 Voting of HealthCare Common Stock. 

(a) From the date of the Distribution until the date that the GE Group ceases to own any Retained Shares, GE shall, and shall cause each member
of the GE Group to (in each case, to the extent that they own any Retained Shares), be present, in person or by proxy, at each and every HealthCare stockholder meeting, and otherwise to cause all Retained Shares owned by them to be counted as
present for purposes of establishing a quorum at any such meeting, and to vote or consent on any matter (including waivers of contractual or statutory rights), or cause to be voted or consented on any such matter, all such Retained Shares in
proportion to the votes cast by the other holders of HealthCare Common Stock on such matter. 
 (b) From the date of the Distribution until
the date that the GE Group ceases to own any Retained Shares, GE hereby grants, and shall cause each member of the GE Group (in each case, to the extent that they own any Retained Shares) to grant, an irrevocable proxy, which shall be deemed coupled
with an interest sufficient in law to support an irrevocable proxy to HealthCare or its designees, to vote, with respect to any matter (including waivers of contractual or statutory rights), all Retained Shares owned by them, in proportion to the
votes cast by the other holders of HealthCare Common Stock on such matter; provided that (i) such proxy shall automatically be revoked as to a particular Retained Share upon any Sale of such Retained Share from a member of the GE Group
to a Person other than a member of the GE Group and (ii) nothing in this Section 3.1(b) shall limit, restrict or prohibit any such Sale. 

ARTICLE IV 

MISCELLANEOUS 
 4.1
Term. This Agreement shall terminate upon such time as there are no Registrable Securities, except for the provisions of Section 2.8 and Section 2.9 and all of this Article IV, which
shall survive any such termination. 
 4.2 Notices. All notices or other communications under this Agreement shall be in writing and
shall be deemed to be duly given (a) when delivered in person, (b) on the date received, if sent by a nationally recognized delivery or courier service, (c) upon written confirmation of receipt after transmittal by electronic mail
(followed by delivery of an original via overnight courier service) or (d) upon the earlier of confirmed receipt or the fifth (5th) business day following the date of mailing if sent by
registered or certified mail, return receipt requested, postage prepaid and addressed as follows: 
 To GE: 

General Electric Company 
 5 Necco
Street 
 Boston, MA 02210 

  
 23 













 Attn:        [***] 

      [***] 

Email:     [***] 

with a copy to: 
 Paul, Weiss,
Rifkind, Wharton & Garrison LLP 
 1285 Avenue of the Americas 

New York, NY 10019-6064 

Attn:      Scott A. Barshay 

    Steven J. Williams 

Email:   sbarshay@paulweiss.com 

    swilliams@paulweiss.com 

To GE HealthCare Technologies Inc.: 

GE HealthCare Technologies Inc. 

500 W. Monroe Street 
 Chicago,
Illinois 60661 
 Attn:     [***] 

   [***] 
 Email:
 [***] 
 Either party may, by notice to the other party, change the address and identity of the Person to which such notices and copies of such
notices are to be given. Each party agrees that nothing in this Agreement shall affect the other party’s right to serve process in any other manner permitted by Law (including pursuant to the rules for foreign service of process authorized by
the Hague Convention). 
 4.3 Successors, Assigns and Transferees. 

(a) The provisions of this Agreement and the obligations and rights hereunder shall be binding upon, inure to the benefit of and be enforceable
by (and against) the parties and their respective successors and permitted assigns. HealthCare may assign this Agreement at any time in connection with a Sale or acquisition of HealthCare, whether by merger, consolidation, Sale of all or
substantially all of HealthCare’s assets, or similar transaction, without the consent of the Holders; provided that the successor or acquiring Person agrees in writing to assume all of HealthCare’s rights and obligations under this
Agreement. GE may assign this Agreement to any member of the GE Group or at any time in connection with a sale or acquisition of GE, whether by merger, consolidation, sale of all or substantially all of GE’s assets, or similar transaction,
without the consent of HealthCare. 

  
 24 













 (b) In connection with any Sale of Registrable Securities, GE may assign its rights and
obligations under this Agreement, other than its rights and obligations contained in Article III (such assignable rights and obligations, the “Registration-Related Rights and Obligations”) relating to such Registrable
Securities to the following transferees in such Sale: (i) a member of the GE Group to which Registrable Securities are Sold; (ii) one or more Participating Banks to which Registrable Securities are Sold; (iii) any other transferee to
which Registrable Securities are Sold, if HealthCare provides prior written consent to the transfer of such Registration-Related Rights and Obligations along with the Sale of Registrable Securities; or (iv) any other transferee that acquires at
least five percent (5%) of the outstanding shares of HealthCare Common Stock immediately following the completion of the Distribution; provided, that in the case of clauses (i), (ii), (iii) or (iv), (x) HealthCare is given written notice
prior to or at the time of the completion of such Sale stating the name and address of the transferee and identifying the securities with respect to which the Registration-Related Rights and Obligations are being Sold and (y) the transferee
executes a counterpart in the form attached hereto as Exhibit A and delivers the same to HealthCare (any such transferee in such Sale, a “Transferee”). In connection with the Sale of Registrable Securities, a Transferee or
Subsequent Transferee (as defined below) may assign its Registration-Related Rights and Obligations under this Agreement relating to such Registrable Securities to the following subsequent transferees: (A) an Affiliate of such Transferee to
which Registrable Securities are Sold, (B) any subsequent transferee to which Registrable Securities are Sold, if HealthCare provides prior written consent to the transfer of such Registration-Related Rights and Obligations along with the Sale
of Registrable Securities or (C) any other subsequent transferee that acquires at least five percent (5%) of the outstanding shares of HealthCare Common Stock immediately following the completion of the Distribution; provided, that in
the case of clauses (A), (B) or (C), (x) HealthCare is given written notice prior to or at the time of such Sale stating the name and address of the subsequent transferee and identifying the securities with respect to which the Registration-Related
Rights and Obligations are being assigned and (y) the subsequent transferee executes a counterpart in the form attached hereto as Exhibit A and delivers the same to HealthCare (any such subsequent transferee, a “Subsequent
Transferee”). 
 4.4 GOVERNING LAW; NO JURY TRIAL. 

(a) This Agreement and any disputes relating to, arising out of or resulting from this Agreement, including to its execution, performance, or
enforcement, shall be governed by, and construed and enforced in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws thereof. 

(b) In the event of any claim, controversy, demand or request for relief of any kind arising out of, in connection with, or in relation to the
interpretation, performance, nonperformance, validity or breach of this Agreement or otherwise arising out of or related to this Agreement or the transactions contemplated hereby, including any Action based on contract, tort, equity, statute,
regulation or constitution (collectively, “Disputes”), the party raising the Dispute shall give written notice of the Dispute (a “Dispute Notice”), and the general counsels of the parties (or such other individuals
designated by the respective general counsels) or the executive officers designated by the parties shall negotiate for a reasonable period of time to settle such Dispute; provided, that such reasonable period shall not, unless otherwise
agreed by the parties in writing, exceed ninety (90) days (the “Negotiation Period”) from the time of receipt of the Dispute Notice; provided, further, that in the event of any arbitration in accordance with


  
 25 













 
Section 4.4(c), the parties shall not assert the defenses of statute of limitations, laches and any other defense, in each such case based on the passage of time during
the Negotiation Period, and any contractual time period or deadline under this Agreement relating to such Dispute occurring after the Dispute Notice is received shall not be deemed to have passed until such arbitration has been resolved. 

(c) If the Dispute has not been resolved for any reason after the Negotiation Period, such Dispute may be submitted by either party to final
and binding arbitration administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures then in effect (the “Rules”), except as provided in Section 4.5 or as otherwise modified herein.

 (i) The arbitration shall, subject to the terms and conditions set forth in a schedule to the Separation and Distribution Agreement, be
conducted using a single arbitrator selected from the list set forth on, and in accordance with the provisions of, such schedule. 
 (ii) If
none of the arbitrators listed on and selected in accordance with the schedule to the Separation and Distribution Agreement referred to in Section 4.4(c)(i) is available or willing to serve, then the arbitration shall be
conducted by a three-member arbitral tribunal (such three-member arbitral tribunal or single arbitrator selected pursuant to Section 4.4(c)(i), as applicable, the “Arbitral Tribunal”). In this event, the
claimant shall nominate one arbitrator in accordance with the Rules, and the respondent shall nominate one arbitrator in accordance with the Rules within twenty-one (21) days after the appointment of the
first arbitrator. The third arbitrator, who shall serve as chair of the Arbitral Tribunal, shall be jointly nominated by the two party-nominated arbitrators within twenty-one (21) days after the
confirmation of the appointment of the second arbitrator or such additional period as may be mutually agreed. If any arbitrator is not appointed within the time limit provided herein, such arbitrator shall be appointed by JAMS in accordance with the
listing, striking and ranking procedure in the Rules. 
 (iii) The arbitration shall be held, and the award shall be rendered, in New York,
New York, in the English language. 
 (iv) For the avoidance of doubt, by submitting their Dispute to arbitration under the Rules, the
parties expressly agree that all issues of arbitrability, including all issues concerning the propriety and timeliness of the commencement of the arbitration, the jurisdiction of the Arbitral Tribunal (including the scope of this agreement to
arbitrate and the extent to which a Dispute is within that scope), and the procedural conditions for arbitration, shall be finally and solely determined by the Arbitral Tribunal. 

(v) Without derogating from Section 4.4(c)(vi) below, the Arbitral Tribunal shall have the full authority to grant
any pre-arbitral injunction, pre-arbitral attachment, interim or conservatory measure or other order in aid of arbitration proceedings (“Interim
Relief”). The parties shall exclusively submit any application for Interim Relief to only: (A) the Arbitral Tribunal; or (B) prior to the constitution of the Arbitral Tribunal, an emergency arbitrator appointed in the manner
provided for in the Rules (the “Emergency Arbitrator”). Any Interim Relief so issued shall, to the extent 

  
 26 













 
permitted by applicable Law, be deemed a final arbitration award for purposes of enforceability, and, moreover, shall also be deemed a term and condition of this Agreement subject to specific
performance in Section 4.5 below. The foregoing procedures shall constitute the exclusive means of seeking Interim Relief, provided, however, that (i) the Arbitral Tribunal shall have the power to
continue, review, vacate or modify any Interim Relief granted by an Emergency Arbitrator; and (ii) in the event an Emergency Arbitrator or the Arbitral Tribunal issues an order granting, denying or otherwise addressing Interim Relief (a
“Decision on Interim Relief”), any party may apply to enforce or require specific performance of such Decision on Interim Relief in any court of competent jurisdiction. 

(vi) The Arbitral Tribunal shall have the power to grant any remedy or relief that is in accordance with the terms of this Agreement,
including specific performance and temporary or final injunctive relief, provided, however, that the Arbitral Tribunal shall have no authority or power to limit, expand, alter, amend, modify, revoke or suspend any condition or
provision of this Agreement, nor any right or power to award punitive, exemplary, enhanced or treble damages. 
 (vii) The Arbitral Tribunal
shall have the power to allocate the costs and fees of the arbitration, including reasonable attorneys’ fees and expenses and costs as well as those costs and fees addressed in the Rules, between the parties in the manner it deems fit. 

(viii) Arbitration under this Section 4.4 shall be the sole and exclusive remedy for any Dispute, and any award
rendered thereby shall be final and binding upon the parties as from the date rendered. Judgment on the award rendered by the Arbitral Tribunal may be entered in any state or federal court within the State of Delaware (which the parties hereby agree
have jurisdiction over them to enforce any such award) and any other court having jurisdiction thereof, including any court having jurisdiction over the relevant Party or its Assets. 

4.5 Specific Performance. Subject to Section 4.4(b) and Section 4.4(c)), except as
provided below, in the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement, the affected party shall have the right to specific performance, declaratory relief and injunctive or
other equitable relief (on a permanent, emergency, temporary, preliminary or interim basis) of its rights under this Agreement, in addition to any and all other rights and remedies at Law or in equity, and all such rights and remedies shall be
cumulative. The other party shall not oppose the granting of such relief on the basis that money damages are an adequate remedy. The parties agree that the remedies at Law for any breach or threatened breach hereof, including monetary damages, are
inadequate compensation for any loss and that any defense in any action for specific performance that a remedy at Law would be adequate is hereby waived. Any requirements for the securing or posting of any bond or similar security with such remedy
are hereby waived. For the avoidance of doubt, the rights pursuant to this Section 4.5 shall be pursued in arbitration under Section 4.4(c). 

4.6 Venue for Injunctive Relief and Specific Performance Claims. Notwithstanding anything to the contrary in this Agreement (including,
for the avoidance of doubt, Section 4.4(b) and Section 4.4(c)), an affected party may bring any claim for specific performance, declaratory relief and injunctive or other equitable relief (on a
permanent, emergency, temporary, preliminary or interim basis) under Section 4.5 of this Agreement (a “Chosen Court 

  
 27 













 
Claim”) either (a) pursuant to the procedures contained in Section 4.4(b) and Section 4.4(c); or (b) at the affected
party’s sole discretion, in the Delaware Court of Chancery (or, if the Delaware Court of Chancery shall be unavailable, any Delaware State court or the federal court sitting in the State of Delaware) (the “Chosen
Courts”). The parties irrevocably consent and agree, on behalf of themselves and their Affiliates, to the jurisdiction, forum and venue of the Chosen Courts for a Chosen Court Claim, and agree that they shall not assert, and shall
hereby waive, any claim or right or defense that they are not subject to the jurisdiction of the Chosen Courts, that the venue is improper, that the forum is inconvenient, that the Chosen Court Claim should instead be arbitrated by their agreement
or operation of law, or any similar objection, claim or argument. 
 4.7 Headings. The article, section and paragraph headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

4.8 Severability. If any provision of this Agreement or the application thereof to any Person or circumstance is determined by an
arbitrator or court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to Persons or circumstances, or in jurisdictions other than those as to which it has been held
invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to either party. Upon any such determination, any such provision, to the extent determined to be invalid, void or unenforceable, shall be deemed replaced by a provision that such arbitrator or court determines is valid and
enforceable and that comes closest to expressing the intention of the invalid, void or unenforceable provision. 
 4.9 Amendment;
Waiver. 
 (a) This Agreement may not be amended or modified and waivers and consents to departures from the provisions hereof may not be
given, except by an instrument or instruments in writing making specific reference to this Agreement and signed by HealthCare and the Holders of a majority of the Registrable Securities; provided that if GE or any of its Affiliates owns
Registrable Securities, no amendment to or waiver of any provision in this Agreement will be effected without the written consent of GE if such amendment or waiver adversely affects (in whole or in part) any rights of GE or such Affiliates of GE.

 (b) No failure to exercise and no delay in exercising, on the part of any party, any right, remedy, power or privilege hereunder shall
operate as a waiver hereof or thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or
privilege. 
 4.10 Registrations, Exchanges, etc. Notwithstanding anything to the contrary that may be contained in this Agreement,
the provisions of this Agreement shall apply to the full extent set forth herein with respect to (a) any shares of HealthCare Common Stock, now or hereafter authorized to be issued, (b) any and all securities of HealthCare into which the
shares of HealthCare Common Stock are converted, exchanged or substituted in any 

  
 28 













 
recapitalization or other capital reorganization by HealthCare and (c) any and all securities of any kind whatsoever of HealthCare or any successor or permitted assign of HealthCare (whether
by merger, consolidation, Sale of assets or otherwise) which may be issued on or after the date hereof in respect of, in conversion of, in exchange for or in substitution of, the shares of HealthCare Common Stock, and shall be appropriately adjusted
for any stock dividends, or other distributions, stock splits or reverse stock splits, combinations, recapitalizations, mergers, consolidations, exchange offers or other reorganizations occurring after the date hereof. 

4.11 Further Assurances. In addition to the actions specifically provided for elsewhere in this Agreement, but subject to the express
limitations of this Agreement, each of the parties shall use reasonable best efforts, prior to, on and after the Distribution, to take, or cause to be taken, all actions, and to do, or cause to be done, all things, reasonably necessary, proper or
advisable under applicable Laws and agreements to consummate, and make effective, the transactions contemplated by this Agreement. 
 4.12
Counterparts. This Agreement may be executed in one or more counterparts, all of which counterparts shall be considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each party and
delivered to the other party. This Agreement may be executed by facsimile or PDF signature and scanned and exchanged by electronic mail, and such facsimile or PDF signature or scanned and exchanged copies shall constitute an original for all
purposes. 
 [The remainder of page intentionally left blank. Signature page follows.] 

  
 29 













 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first written above. 
  

			
	GENERAL ELECTRIC COMPANY
		
	By:	 	 
		 	Name:
		 	Title:
	
	GE HEALTHCARE TECHNOLOGIES INC.
		
	By:	 	 
		 	Name:
		 	Title:



  
 [Signature Page to
Stockholder and Registration Rights Agreement]